New Delhi, India -- (SBWIRE) -- 12/05/2017 -- Systemic Lupus Erythematosus (SLE) is a chronic, multisystem, inflammatory autoimmune disease which leads to weakening of the immune system. It results in systemic inflammation which affects multiple organs such as kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain. Acute Cutaneous Lupus, Chronic or Discoid Lupus, Lupus Panniculitis, Lupus Pernio, Subacute Cutaneous Lupus and Tumid Lupus are the most common form of Systemic Lupus Erythematosus.
According to the latest report of DelveInsight, "Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology and Market Forecast-2025", the prevalent population of SLE is expected to grow at a CAGR of 3.02% from 2015-2025. The prevalence of SLE is observed to be higher in the United States as compared to EU5 and Japan. With very less approved drugs SLE market was dominated by off-label drugs before the approval of Benlysta in 2011. GSK's (Benlysta) is the second drug approved by the FDA after Plaquenil (Hydrochloroquine; Sanofi-Aventis) that received approval in 1955 and was the first drug approved for the treatment of SLE. Some of the off-label therapies include Corticosteroids, NSAIDs, Anti-malarials, Biologics (mainly, rituximab) and Immunosuppressants.
Some of the major upcoming targeted therapies include Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Atacicept (Merck KgaA), IFN? KINOID (Neovacs), Vobarilizumab (Ablynx-Abbvie) and CC-220 (Celgene). With the approval of upcoming drugs the market size of SLE is expected to grow at a CAGR of 19% from 2015-2025. There were many other molecules that were considered to be a game changer but failed to work like one. Therapies that failed to become a game changer are Blisibimod (Anthera/Amgen), Abatacept (BMS) and even Rituximab. The respective companies have discontinued the development of Blisibimod, Abatacept for the treatment of SLE. However, Rituximab is still extensively used as 'off-label' drug for the treatment.
The latest report has covered detailed description about Disease Diagnostics, Diagnosis Criteria, and Treatment. Complete Pipeline drugs profiling covering each and every phase of development with clinical trials data. Total market size of Systemic Lupus Erythematosus is provided covering the 7MM to better understand the areas of improvement and growth opportunities in the market. Complete Epidemiology and patient population details are provided covering the 7MM to better understand the major market scenario. Report has covered all the unmet needs in the current domain to understand the areas of improvement. Details about all the possible market drivers and barriers is also provided to better understand to plan the strategies accordingly.
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the SLE market.
- To understand the future market competition in the SLE market and Insight reviews of the key market drivers and barriers.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.
Companies Covered:
- Human Genome Sciences
- ImmuPharma
- AstraZeneca
- Merck KgaA
- Neovacs
- Ablynx-Abbvie
- Celgene
- GlaxoSmithKline
And many others
Table of Contents:
Report Introduction
Systemic Lupus Erythematosus Market Overview at a Glance
Market Share Distribution of Systemic Lupus Erythematosusin 2016
Market Share Distribution of Systemic Lupus Erythematosusin 2025
Total Prevalent Cases of Systemic Lupus Erythematosus - by Country (2016)
Total Market by Region of Systemic Lupus Erythematosus (2016 & 2025)
Disease Background and Overview: Systemic Lupus Erythematosus
Introduction
Clinical Manifestations
Etiology
Pathogenesis
Symptoms
Diagnosis
Diagnostic Criteria for Systemic Lupus Erythematosus
Epidemiology and Patient Population
Prevalent Population of Systemic Lupus Erythematosus in 7MM
Prevalent Population of Systemic Lupus Erythematosus in 7MM – By Region
Prevalent Population of Systemic Lupus Erythematosus in 7MM – Distribution (2016)
Prevalent Population of Systemic Lupus Erythematosus in 7MM – Distribution (2025)
Epidemiology of Systemic Lupus Erythematosus
United States
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
EU5
Germany
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
France
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
United Kingdom
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
Spain
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
Italy
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
Japan
Prevalent Population of Systemic Lupus Erythematosus
Sex-Specific Prevalence of Systemic Lupus Erythematosus
Treatment Practices
Treatment goals
Treatment Algorithm
American Family Physician: Recommendation for SLE
European League against Rheumatism (EULAR): Recommendations for SLE
Marketed Drugs
Benlysta (belimumab): Human Genome Sciences
Drug Description
Mechanism of Action
Regulatory Milestones
Advantages & Disadvantages
Safety and Efficacy
Pharmacokinetics and Pharmacodynamics
Product Profile
Marketed Drug List Continued…
Emerging Therapies
Emerging Drugs Analysis
Lupuzor: ImmuPharma plc
Regulatory Milestones
Other development activities
Clinical Development
Clinical Trials Information
Product Profile
Emerging Drug List Continued…
Current Unmet Need
Systemic Lupus Erythematosus: Market Analysis
Market size of Systemic Lupus Erythematosusin 7MM (2016)
Market size of Systemic Lupus Erythematosusin 7MM (2025)
Systemic Lupus Erythematosus: 7 Major Market Outlook
Market size of Systemic Lupus Erythematosusin 7MM
Systemic Lupus Erythematosus: US Market Outlook
US Market size
Systemic Lupus Erythematosus: EU5 Market Outlook
Germany Market size
France Market size
United Kingdom Market size
Spain Market size
Italy Market size
Systemic Lupus Erythematosus: Japan Market Outlook
Japan Market size
Market Drivers
Market Barriers
Appendix
Report Methodology
Sources Used
Consulting Services
Disclaimer
About DelveInsight